Physician profile
Judith Hall
NPI 1992806178
$2,611.50
in general payments reported to CMS, 2019-2025
28 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $459 · 2022: $344 · 2023: $780 · 2024: $734 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.81 |
| Education | $107.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $504.43 | 2021-2025 | Farxiga, Lokelma |
| Amgen INC. | $341.69 | 2024-2025 | Krystexxa, Tavneos, Evenity |
| Abbvie INC. | $293.60 | 2023 | |
| Novo Nordisk INC | $231.77 | 2021-2023 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $145.82 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.02 | 2021-2025 | Jardiance |
| Astellas Pharma US INC | $118.14 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $101.64 | 2021-2025 | |
| Intuitive Surgical, INC. | $98.09 | 2024 | |
| Alexion Pharmaceuticals, INC. | $72.46 | 2022-2025 | Ultomiris |
| Vifor Pharma, INC. | $65.15 | 2021-2024 | Veltassa |
| Fresenius USA Marketing, INC. | $62.97 | 2022-2024 | Velphoro |
| Ardelyx, INC. | $62.16 | 2023-2024 | Ibsrela |
| Dexcom, INC. | $45.26 | 2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $44.84 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $40.49 | 2021-2022 | |
| Glaxosmithkline, LLC. | $37.10 | 2021-2022 | |
| Kyowa Kirin, INC. | $28.04 | 2023 | Crysvita |
| Mallinckrodt Hospital Products INC. | $26.07 | 2021-2023 | Acthar |
| Inspire Medical Systems, INC. | $21.61 | 2023 | Inspire |
| Aurinia Pharma U.S., INC. | $20.44 | 2023 | Lupkynis |
| Amag Pharmaceuticals, INC. | $19.33 | 2021 | |
| Apellis Pharmaceuticals, INC. | $19.21 | 2025 | |
| Calliditas Therapeutics US INC. | $18.58 | 2023 | Tarpeyo |
| Sanofi-Aventis U.S. LLC | $17.64 | 2021 | |
| Opko Pharmaceuticals, LLC | $17.30 | 2025 | Rayaldee |
| Alnylam Pharmaceuticals INC. | $15.56 | 2021 | |
| Horizon Therapeutics Plc | $13.09 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.